← Back

IQWiG (German HTA) · Germany · 28 Apr 2026 · Guidance

Acupuncture for migraine prophylaxis: benefit limited to narrow therapeutic indication

Original title: Acupuncture for migraine prophylaxis: benefit limited to a narrow thera-peutic indication – studies are lacking for the majority of indications

AI-generated summary

IQWiG assessed manual acupuncture for migraine prevention in adults on behalf of Germany's Federal Joint Committee, comparing it with preventive medications and with no treatment. The final report, published in August 2026, found no relevant studies for most therapeutic indications and evidence of benefit only for a narrow indication comparing acupuncture to older drugs flunarizine and topiramate. No studies exist comparing acupuncture with commonly used beta-blockers, amitriptyline, botulinum toxin, or newer CGRP-targeted antibodies.

From IQWiG (German HTA)

Up-to-date clinical studies are essential for a good benefit assessment. This can also be seen in the example of manual acupuncture for migraine prophylaxis.

On behalf of the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) assessed the benefit of manual acupuncture for migraine prophylaxis in adults, compared with migraine prevention medication. A second comparison investigated whether, for people who cannot use prophylaxis medication, acupuncture is more effective than no prophylaxis.

Publication date original (German-language) report: 28 April 2026; English translation: August 2026

Currently, people who suffer from frequent migraine attacks receive various prophylactic medications, e.g. propranolol and metoprolol (beta-blockers), flunarizine, topiramate, amitriptyline or a botulinum toxin. If this prophylaxis does not provide sufficient help, antibodies that target the calcitonin gene-related peptide (CGRP)have also been available as a second-line treatment since 2019. Prophylaxis can be supported by non-drug methods, such as behavioural therapy or psychological interventions. Acupuncture has long been the subject of discussion as an alternative form of prophylaxis: As many as 20 years ago, Germany’s statutory health insurance funds commissioned a large-scale study.

IQWiG's final report, which has now been published, shows that there are no relevant studies for the majority of therapeutic indications of manual acupuncture for migraine prevention. This applies both to patients for whom drug therapy is not (or is no longer) an option, and to those for whom drug therapy with conventional drugs does not provide adequate symptom control and for whom second-line treatment with CGRP-targeted therapies is being conducted or is under consideration. There is therefore no proof of a benefit of manual acupuncture using needles in these two therapeutic indications.

Informative studies only exist for the comparison of manual acupuncture with individual conventional drugs – specifically the older drugs flunarizine and topiramate. However, as for various reasons the use of topiramate and flunarizine is limited in clinical practice, these studies only allowed an advantage of acupuncture to be derived for a narrow therapeutic indication. There are no studies comparing acupuncture with other conventional, approved medicines such as beta-blockers, amitriptyline or onabotulinum toxin A.

Excerpt from the official page. The original is authoritative. Continue reading at IQWiG (German HTA) ↗